Art. -Nr.: HY-155864

AJ2-30

Kundenbewertung

Based on 1 Customer Validation

AJ2-30 is a SLCl5A4 inhibitor. AJ2-30 inhibits endolysosomal TLR7-9-mediated mTOR activation. AJ2-30 blocks endogenous NOD signaling. AJ2-30 can be used in inflammation studies.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.72%
CAS. Nr.: 2700322-79-6
Formel: C₂₃H₂₂N₄
Molecular Weight:354.45

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

AJ2-30 Chemical Structure

CAS. Nr.: 2700322-79-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

AJ2-30 is a SLCl5A4 inhibitor. AJ2-30 inhibits endolysosomal TLR7-9-mediated mTOR activation. AJ2-30 blocks endogenous NOD signaling. AJ2-30 can be used in inflammation studies^[1]^[2].

Alle NOD-like Receptor (NLR) Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

In Vitro

AJ2-30 (5 μM, 24 h) inhibits TLR7/8-induced production of TNFα in human monocytes^[2].
AJ2-30 (5 μM, 24 h) inhibits TLR7, TLR7/8, and TLR9-induced IFN-α production in human plasmacytoid dendritic cells (pDCs)^[2].
AJ2-30 (5 μM) inhibits bacterial dipeptides MDP and TriDAP-mediated NOD1 and NOD2 signaling in primary human macrophages^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

human B cells
Concentration:

2, 5, 10 μM
Incubation Time:

4 h
Result:

Did not block activation of the mTOR pathway upon stimulation with the TLR2 agonist Pam3CSK4.
Reduced the activation of the mTOR pathway in human B cells stimulated with TLR7/8 or TLR9 agonists.

In Vivo

Did not block activation of the mTOR pathway upon stimulation with the TLR2 agonist Pam3CSK4.
Reduced the activation of the mTOR pathway in human B cells stimulated with TLR7/8 or TLR9 agonists.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J mice (8-12-week-old) challenged with TLR9 ligand CpG-A complexed with DOTAP^[2]
Dosage:

50 mg/kg
Administration:

Intraperitoneal injection, prior to CpG-A
Result:

Significantly reduced the levels of IFN-α, IFN-β, and IFN-γ in the serum 6 h after CpG-A/DOTAP administration.
Inhibited the phosphorylation of mTOR and 4E-BP1 in splenic pDCs 2 h after CpG-A/DOTAP administration.

Chemical Information

CAS. Nr. 2700322-79-6
Appearance Solid
Molecular Weight 354.45
Formel C₂₃H₂₂N₄
Color White to off-white
SMILES

CCN1C2=C(C=CC=C2)C3=CC(CNC4=NC5=C(N4C)C=CC=C5)=CC=C31
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (141.06 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8213 mL

14.1064 mL

28.2127 mL

5 mM

0.5643 mL

2.8213 mL

5.6425 mL

10 mM

0.2821 mL

1.4106 mL

2.8213 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Daniel Lazar, et al. Small molecule inhibitors of scl15a4 with anti-inflammatory activity. Patent. WO2021174023.

[2]. Chiu TY, et al. Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity. Nat Chem Biol. 2024 Aug;20(8):1000-1011. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8213 mL	14.1064 mL	28.2127 mL	70.5318 mL
	5 mM	0.5643 mL	2.8213 mL	5.6425 mL	14.1064 mL
	10 mM	0.2821 mL	1.4106 mL	2.8213 mL	7.0532 mL
	15 mM	0.1881 mL	0.9404 mL	1.8808 mL	4.7021 mL
	20 mM	0.1411 mL	0.7053 mL	1.4106 mL	3.5266 mL
	25 mM	0.1129 mL	0.5643 mL	1.1285 mL	2.8213 mL
	30 mM	0.0940 mL	0.4702 mL	0.9404 mL	2.3511 mL
	40 mM	0.0705 mL	0.3527 mL	0.7053 mL	1.7633 mL
	50 mM	0.0564 mL	0.2821 mL	0.5643 mL	1.4106 mL
	60 mM	0.0470 mL	0.2351 mL	0.4702 mL	1.1755 mL
	80 mM	0.0353 mL	0.1763 mL	0.3527 mL	0.8816 mL
	100 mM	0.0282 mL	0.1411 mL	0.2821 mL	0.7053 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AJ2-30

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Membrane Transporter/Ion Channel Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

High-Throughput Bioactive Compound Library

Pattern Recognition Receptors Library

Lactylation Compound Library

Alle NOD-like Receptor (NLR) Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AJ2-30 Related Classifications

HY-155864 Related Classifications